Search Result

Results for "

Ataxia+telangiectasia+mutated

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ATM/ATR (6) Apoptosis (1) Checkpoint Kinase (Chk) (2) Choline Kinase (1) DNA/RNA Synthesis (2) Dystrophin (1) Histone Methyltransferase (1)
By Research Areas:	Cancer (8)

Inhibitors & Agonists

Antibodies

Targets Recommended: ATM/ATR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-157941

ART0380	ATM/ATR Checkpoint Kinase (Chk) DNA/RNA Synthesis	Cancer
ART0380 is a potent, selective and orally active ATR kinase inhibitor. ART0380 potently inhibits human ATR-ATRIP complex with an IC₅₀ of 51.7 nM. ART0380 binds the ATP pocket of the ATR-ATRIP complex, blocks ATR-dependent Chk1 serine 345 phosphorylation, and induces cell cycle disorder and DNA damage. ART0380 demonstrates potent and selective antitumor activity in preclinical models with varying types of ataxia-telangiectasia mutated (ATM) gene aberrancy. ART0380 can be used for the research of cancer, such as colorectal cancer and prostate cancer .

HY-16705

BRD4770 5 Publications Verification	Histone Methyltransferase	Cancer
BRD4770 is a histone methyltransferase G9a inhibitor. BRD4770 reduces di- and trimethylation of lysine 9 on histone H3 (H3K9) with an EC₅₀ of 5 μM, and has less or little effect toward H3K27me3, H3K36me3, H3K4me3, and H3K79me3. BRD4770 can activate the ataxia telangiectasia mutated (ATM) pathway and induce cell senescence .

HY-19323A

(S)-Ceralasertib 2 Publications Verification (S)-AZD6738	ATM/ATR	Cancer
(S)-Ceralasertib ((S)-AZD6738) is the S-enantiomer of Ceralasertib (HY-19323). (S)-Ceralasertib is the inhibitor for ataxia telangiectasia mutated and rad3 related (ATR) .

HY-145312

ATR-IN-4	ATM/ATR	Cancer
ATR-IN-4 is a potent ATR (Ataxia telangiectasia mutated gene Rad 3-associated kinase) inhibitor. ATR-IN-4 inhibits growth of human prostate cancer cells DU145 and human lung cancer cells NCI-H460 with IC₅₀s of 130.9 nM and 41 .33 nM, respectively. (Patent CN112142744A, compound 13) .

HY-144214

ATR-IN-10	ATM/ATR	Cancer
ATR-IN-10 is a potent and highly selective inhibitor of ataxia telangiectasia mutated and Rad3-Related (ATR) kinase with an IC₅₀ value of 2.978 μM.

HY-123359

RTC14	DNA/RNA Synthesis Dystrophin	Others
RTC14 is a read-through compound (RTC) that can induce ribosomes to bypass nonsense mutations in mRNA and allow the production of full-length functional proteins. RTC14 has the potential to be used in the research of various genetic disorders, such as nonsense mutations in the ataxia-telangiectasia mutated (ATM) gene and the dystrophin gene .

HY-112477

Chk2-IN-1 Hymenialdisine analogue-1	Checkpoint Kinase (Chk) Choline Kinase	Cancer
Chk2-IN-1 (compound 1) is a potent and selective inhibitor of checkpoint kinase 2 (Chk2), with IC₅₀s of 13.5 nM and 220.4 nM for Chk2 and Chk1, respectively. Chk2-IN-1 can elicit a strong ataxia telangiectasia mutated (ATM)-dependent Chk2-mediated radioprotection effect .

HY-141478

Antitumor agent-28	ATM/ATR	Cancer
Antitumor agent-28 selectively inhibits ataxia telangiectasia mutated (ATM) kinase. Antitumor agent-28 prevents ATM mediated disease and has potent anti-cancer activity .

HY-149291

ATM Inhibitor-7	ATM/ATR Apoptosis	Cancer
ATM Inhibitor-7 is a potent and selective ataxia-telangiectasia mutated (ATM) inhibitor with an IC₅₀ value of 1.0 nM. ATM Inhibitor-7 induces Apoptosis and cell cycle arrest at G2/M phase when combinanted with CPT-11 (HY-16562). ATM Inhibitor-7 combines with CPT-11 shows antitumor activity .

Host:	Mouse (2) Rabbit (3)
Reactivity:	Human (5) Rat (2) Mouse (2) Monkey (1)
Application:	IHC-P (3) ICC/IF (4) IP (2) WB (4) FC (1) ELISA (3)
Isotype:	IgG (3) IgG2b (1)
Conjugation:	Non-conjugated (5)
Clonality:	Monoclonal (4) Recombinant (2)
Modification:	Phosphorylated (1) Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86109

	ATM Antibody (YA5801) ATM; Serine-protein kinase ATM; Ataxia telangiectasia mutated; A-T mutated	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat
	ATM Antibody (YA5801) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ATM.

HY-P85049

	ATM Antibody (YA4741) ATM; Serine-protein kinase ATM; Ataxia telangiectasia mutated; A-T mutated	WB, ELISA	Human
	ATM Antibody (YA4741) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to ATM.

HY-P83436

	Phospho-ATM (Ser1981) Antibody (YA3181) ATM; Serine-protein kinase ATM; Ataxia telangiectasia mutated; A-T mutated	WB, IHC-P, ICC/IF, IP	Human
	Phospho-ATM (Ser1981) Antibody (YA3181) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-ATM (Ser1981).

HY-P80023

	ATM Antibody (YA597) Serine-protein kinase ATM, Ataxia telangiectasia mutated, A-T mutated, ATM	WB, ICC/IF, IHC-P	Human
	ATM Antibody (YA597) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ATM.

HY-P84535A

	ATM Antibody (YA4232)(PBS only) AT1; ATA; ATC; ATD; ATE; ATDC; TEL1; TELO1; ATM; Serine-protein kinase ATM; Ataxia telangiectasia mutated; A-T mutated; ATM; Serine-protein kinase ATM; Ataxia telangiectasia mutated; A-T mutated	IHC-P, ICC/IF, FC, ELISA	Human, Mouse, Monkey, Rat
	ATM Antibody (YA4232) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to ATM.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.